247 related articles for article (PubMed ID: 29947961)
1. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.
Ruiu R; Rolih V; Bolli E; Barutello G; Riccardo F; Quaglino E; Merighi IF; Pericle F; Donofrio G; Cavallo F; Conti L
Cancer Immunol Immunother; 2019 Jan; 68(1):131-141. PubMed ID: 29947961
[TBL] [Abstract][Full Text] [Related]
2. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.
Lanzardo S; Conti L; Rooke R; Ruiu R; Accart N; Bolli E; Arigoni M; Macagno M; Barrera G; Pizzimenti S; Aurisicchio L; Calogero RA; Cavallo F
Cancer Res; 2016 Jan; 76(1):62-72. PubMed ID: 26567138
[TBL] [Abstract][Full Text] [Related]
3. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cell antigens as targets for immunotherapy.
Quaglino E; Conti L; Cavallo F
Semin Immunol; 2020 Feb; 47():101386. PubMed ID: 31932198
[TBL] [Abstract][Full Text] [Related]
5. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
6. Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma.
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Cancer Immunol Res; 2018 Nov; 6(11):1417-1425. PubMed ID: 30143536
[TBL] [Abstract][Full Text] [Related]
7. A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer
Bolli E; O'Rourke JP; Conti L; Lanzardo S; Rolih V; Christen JM; Barutello G; Forni M; Pericle F; Cavallo F
Oncoimmunology; 2018; 7(3):e1408746. PubMed ID: 29399412
[TBL] [Abstract][Full Text] [Related]
8. Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.
Donofrio G; Tebaldi G; Lanzardo S; Ruiu R; Bolli E; Ballatore A; Rolih V; Macchi F; Conti L; Cavallo F
Oncoimmunology; 2018; 7(12):e1494108. PubMed ID: 30524888
[TBL] [Abstract][Full Text] [Related]
9. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
10. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
11. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.
Hu Y; Lu L; Xia Y; Chen X; Chang AE; Hollingsworth RE; Hurt E; Owen J; Moyer JS; Prince ME; Dai F; Bao Y; Wang Y; Whitfield J; Xia JC; Huang S; Wicha MS; Li Q
Cancer Res; 2016 Aug; 76(16):4661-72. PubMed ID: 27325649
[TBL] [Abstract][Full Text] [Related]
13. L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents.
Conti L; Lanzardo S; Ruiu R; Cadenazzi M; Cavallo F; Aime S; Geninatti Crich S
Oncotarget; 2016 Oct; 7(41):66713-66727. PubMed ID: 27579532
[TBL] [Abstract][Full Text] [Related]
14. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity.
Arensman MD; Yang XS; Leahy DM; Toral-Barza L; Mileski M; Rosfjord EC; Wang F; Deng S; Myers JS; Abraham RT; Eng CH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9533-9542. PubMed ID: 31019077
[TBL] [Abstract][Full Text] [Related]
15. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
Lien EC; Ghisolfi L; Geck RC; Asara JM; Toker A
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259101
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
18. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
19. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
